Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Diabetes and Metabolic Syndrome: Clinical Research & Reviews

Diabetes management and specific considerations for patients with diabetes during coronavirus diseases pandemic: A scoping review

Anggi Lukman Wicaksana a, b, *, Nuzul Sri Hertanti c, Astri Ferdiana c, d, Raden Bowo Pramono e, f

a Department of Medical Surgical Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
b The Sleman Health and Demographic Surveillance System (HDSS), Universitas Gadjah Mada, Yogyakarta, Indonesia
c Center for Tropical Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
d Faculty of Medicine, University of Mataram, West Nusa Tenggara, Indonesia
e Department of Internal Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
f Dr. Sardjito General Hospital, Yogyakarta, Indonesia

ARTICLE INFO

Article history:
Received 21 May 2020
Received in revised form 27 June 2020
Accepted 30 June 2020

Keywords:
COVID-19
Diabetes
Diabetes management
Pandemic
Scoping review
Special consideration

ABSTRACT

Background and aims: The global pandemic of coronavirus (COVID-19) affects almost all countries in the world, which potentially alter diabetes management. Many diabetes patients are experiencing barrier of care due to the policy related to COVID-19. This article aims to review the current evidence on diabetes management and specific considerations during the COVID-19 pandemic for people living with diabetes.

Methods: We conducted a scoping review in PubMed, Science Direct, DOAJ and Microsoft Academics databases from January 1 to April 17, 2020. Searching terms included “COVID-19”, “severe acute respiratory syndrome coronavirus 2”, and “Diabetes Mellitus” were used. Only scientific articles discussing diabetes management and specific considerations were selected and extracted.

Results: A total of 7 articles was selected in the analysis. Most were published in diabetes journals (85.71%). All articles (100%) discussed diabetes management and 71.43% of them provided diabetes care applicable for diabetes patients. In addition, specific considerations explored caring for diabetes in children and adolescents, pregnancy, elderly, emergency or critical care, to offer certain concern for raising the awareness.

Conclusions: This review specifies a summary of diabetes management as well as the particular considerations to care people living with diabetes during COVID-19 pandemic. Patients, health care providers, and policy makers could take advantage of the review to assist diabetic people passing through COVID-19 pandemic session with optimum glycemic outcome.

© 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

1. Background

The rapid spreading of COVID-19 globally has extensively brought many consequences on care particularly for patients who have comorbid conditions [1,2]. Diabetes ranked second as the most prevalent comorbidities (9.7%, 95% CI 6.9–12.5%) among COVID-19 patients after cardio-metabolic diseases [1,3,4]. People living with diabetes are at higher risk of having COVID-19 infection and potentially experiencing more severe illness when infected [4,5]. A meta-analysis from China reported that COVID-19 patients with diabetes had twice the risk of intensive care unit (ICU) admission [6] and it makes diabetes as independent predictor of ICU admission or invasive mechanical ventilation in COVID-19 patients [3,7]. A recent systematic review also identified that COVID-19 patients with diabetes is related to an increased risk of ICU admission (OR: 2.79, 95% CI 1.85–4.22, I² = 0%, p < 0.0001) and higher mortality rate (OR 3.21, 95% CI 1.82–5.64, I² = 16%, p < 0.0001) [3].

Maintenance of good glycemic control is an effective approach to prevent COVID-19 transmission in diabetic patients [7,8]. However, in many countries, diabetes control becomes challenging because of the imposing government policy to control transmission such as social distancing and lockdown. Most diabetic people could...
experience barriers in accessing measures for controlling their
glycemic level such as limited access to healthcare, limited avail-
ability of fresh food, and limited physical activity because of
confinement [7]. The COVID-19 during pandemic affects diabetes
management. Diabetes educators, physicians, nurses and other
health care providers, need appropriate and accurate information
to facilitate diabetic patients in taking care of their diabetes amid
the COVID-19 pandemic. Therefore, the aim of this paper is to
provide a review on the appropriate diabetes management during
the COVID-19 pandemic for people living with diabetes. In addition,
this review will identify particular care of diabetes in specific
conditions.

2. Methods

2.1. Study design

Scoping review aims to draw key concepts of available literature
in underpinning a research area. This design was chosen because it
provided a broaden scope of specific field. The scoping review
procedure proposed by Arksey & O'Malley was used [9]. This pro-
cedure suggests five steps for a rigorous review; 1) identifying clear
research aims and searching strategies, 2) identifying appropriate
research papers, 3) selecting research paper, 4) extracting and
charting the data, 5) summarizing, analyzing and presenting the
outcomes on report.

2.2. Literature search strategy

Literature search was conducted extensively by searching in
several databases. Two authors (ALW and NSH) performed inde-
pendently search on PubMed, Science Direct, Directory of Open
Access Journal (DOAJ), and Microsoft Academics databases for li-
teratures published between January 1 and April 17, 2020. The
keywords were adopted from Medical Subheading (MESH) and
used Boolean to improve sensitivity. The following search terms
adopted from MESH were used: (“COVID-19” OR “severe acute
respiratory syndrome coronavirus 2”) AND “Diabetes Mellitus”.
Only English literatures were included for review. Non-scientific
publication, correspondences, news and commentary were
excluded.

2.3. Identification and selection relevant articles

The outcome of two independent searches was compared. Dif-
fERENCE finding were communicated and discussed until the same
numbers of articles were reported. Duplicated articles were
removed. Excel spreadsheet was used to short-list the articles
during selection procedure. Seven articles were included for review
after screening and checking eligibility. The preferred reporting
item for systematic review and meta-analysis (PRISMA) was used as
guidance in reporting the searching process (Fig. 1) [10].

2.4. Data extraction

Included articles were compiled and extracted in an Excel
worksheet. The extracted data included title, authors and date of
publication, country and region, research objective, study design,
target of study, sample size, study setting, data collection, key
findings, research domains and subdomains.

2.5. Summarizing the findings

All the included articles were categorized into two domains i.e.
diabetes management and specific consideration. Diabetes
management refers to all actions to treat, manage and cope with
disease process of diabetes. Specific consideration concerns on such
particular situation that requires thoughtfulness of care. Diabetes
management domain was further classified into six sub-domains
i.e. glycemic control and monitoring, dietary intake, physical ac-
tivity, medication, education, and prevention. Specific consider-
ation was classified into sub-domains of diabetes in children and
adolescents, pregnancy, older people, and emergency or critical
care.

Methodological characteristics of the articles were also evalu-
ated using Excel spreadsheet. Each article will be assessed about
the study design, target of study, sample size, and setting. Then, the
data were classified and presented in the percentage.

3. Results

3.1. Characteristic of published articles

Most articles were published in journal of diabetes and meta-
bolic diseases (85.71%, n = 6) followed by medical virology journal
(14.29%, n = 1). The majority of articles were from Asian region
(57.14%, n = 4) followed by European and American region (28.57%,
n = 2; 14.29%, n = 1, respectively). All articles discussed diabetes
management domain and only 71.43% provided information for
specific consideration domain. Fig. 2 shows the subdomains iden-
tified in the articles. Most articles focused on medication (71.43%)
and only 1 article (14.29%) discussed about COVID-19 preventive
action for diabetes patients. In terms of specific consideration
domain, most articles focused on emergency or critical care
(42.86%).

Most articles used review or unclear study design (42.86%, n = 3
for both). The majority of study targets were patients (57.14%, n = 4)
and located in hospital and community setting (57.14%, n = 4). Most
included studies did not reported sample size (71.43%, n = 5,
Table 1).

3.2. Data extraction of the included articles

Information of data extraction is available in Table 2. All
included articles covered research domains and subdomains
through presenting main findings. Although some included articles
did not provide detail information of study design, sample size, and
data collection; the articles were analyzed and presented since it
covered the research aims.

4. Discussion

4.1. Diabetes management

According to The American Diabetes Association standard of
diabetes care for patients and health care workers, diabetes care
should includes comprehensive medical assessment of comorbid-
ities, lifestyle management, glycemic control, medication, obesity
management, risk reduction, and prevention of diabetes compli-
cation [14–16]. Diabetes management will be discussed according
to these standards of care: glycemic control and monitoring, dietary
intake, physical activity, medication, education, and prevention of
COVID-19 infection in the context of COVID-19 pandemic.

4.1.1. Glycemic control and monitoring

All diabetic patients must maintain glycemic control and
monitoring during the pandemic. Patients with diabetes could
temporarily find difficulties for glycemic control and monitoring
during the lockdown or quarantine. They could have problem on
going an access to medicine and glycemic monitoring materials,
including glucose strips, glucometers, and needles. Thus, it is recommended for diabetic patients to early purchase the glycemic monitoring materials and medicine through online [2,7,8]. A tailored glycemic monitoring for diabetic patients could be adjusted by considering age, existing comorbidity, clinical manifestation, and other risk factors [8]. Glycemic monitoring using capillary blood test is acceptable for people living with diabetes during pandemic [2,7].

All hospitalized COVID-19 patients with diabetes should undergo closed glycemic control and routine blood glucose monitoring. Previous research indicated that COVID-19 patients with diabetes were associated with the poor outcomes of health [3,7]. When they are discharged, blood glucose monitoring is highly recommended amid a 4-week follow up after discharge and they have to avoid exposure to infection [8].

Timing for glycemic control and monitoring can be adjusted for particular occasion. During pandemic, fasting and postprandial blood glucose in diabetes patients who consume oral anti diabetic agent(s) with tolerable outcomes (i.e. stable blood glucose record or fasting blood glucose less than 125 mg/dl or HbA1c less than or equal to 6.5%) could be performed once or twice a week. Meanwhile, for diabetes patients who administer insulin with poor outcomes or intermittent hypoglycemia, blood glucose should be checked at least four times a day i.e. fasting, pre lunch, pre dinner and bedtime. Any sign or symptom of occurring hypoglycemia is reason to immediately check capillary blood glucose. All blood glucose checking should be recorded for a minimum of consecutive three days and communicated to health care providers through tele-consultation [2,7].

---

**Fig. 1.** PRISMA flow chart for scoping review.
4.1.2. Dietary intake

Lockdown during COVID-19 pandemic could affect patient’s dietary habit. Patients with diabetes may find limited access to fresh fruits and vegetables [2,7] and consume canned or packaged foods that are high in calories and/or fats [2]. Healthy and balanced diet should be emphasized and encouraged by dietician to diabetic patients during the consultation [7,13].

The recommended calorie intakes for obese and non-obese diabetes patients are 20 kcal/kg and 22–25 kcal/kg of ideal body weights with sedentary lifestyle, respectively. Dietary advice should include low carbohydrate intake, low fats intake, and optimal protein intake with no meal skipping [13]. Daily diet should be divided into three meals and a snack.

Variation of food composition is recommended, consisting of 50–60% complex carbohydrates, 25–45% fibers, up to 30% fats, 1 g/kg/day (general patients) or 0.8 g/kg/day (nephropathy and macroalbuminuria) of proteins. The use of oils should be no more than 3 teaspoons a day and less than 5 g/day for sodium intake. Patients could also use the diabetes plate method i.e. half plate of vegetables, one-fourth of proteins, and one-fourth of complex carbohydrates. Alcohol, smoking, and sugary sweetened foods should be avoided [7].

4.1.3. Physical activity

Social distancing, lockdown and home confinement require patients with diabetes to limit their activities or regular exercise. However, they could still have limited access to indoor and outdoor physical activities [2]. Home exercise such as treadmill, stationary cycling or jogging and resistance training should be recommended [2,7,13].

Tailored physical activity while quarantine should be practiced about 60 min/day. The intensity and type of activities could be adjusted regarding individual patient’s condition. The recommended physical activity is classified into three exercises i.e. aerobics, flexibility workout, and strength muscle exercises. Aerobic exercise with moderate intensity i.e. brisk walking, treadmill, stationary jogging or cycling, dancing, jumping, sport aerobic, and gardening, is suggested for a minimum of 30 min/day [7,13]. If this is unachievable, patients could take two or three times in small portion of aerobic exercise (10–15 min). Climbing stairs, household routine activities [7] or yoga practice as stretching technique [13] for 15 min/day is recommended as flexibility training [7,13]. A 11 steps of yoga pranayama for chronic condition could be implemented to enhance pulmonary function [17]. A 15 min of squats, push-ups, sit-ups, forward flexes or small weight lift as muscle training exercise every day is recommended as muscle training exercises [7,13]. A physical activity for diabetes patients with heart diseases or hypoglycemia history should be noticed as particular circumstance [7].

4.1.4. Medication

Health care providers need to assess patient’s adherence to medication through tele-consultation using valid but brief tools. They also should make sure that all diabetes patients have sufficient medication stocks and prescribe enough medication because of limited access to clinic during the pandemic [7].

To date, there is no robust evidence of anti diabetic agents in the context of treatment for COVID-19 patients with diabetes though some anti diabetic agents indicate positive outcome of glycemic control. The application of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) is hypothetically useful to treat COVID-19 patients, however, there is still no data to support it. Currently, the Association of European and American Cardiology and Hypertension recommend ACE inhibitors and ARB to treat COVID-19 although it lacks of evidence to support [2].
| Table 2 |
| --- |
| Data extraction of the included articles (n = 7). |
| **Author(s) & date of publication** | **Country/Region** | **Aim** | **Data collection** | **Key findings** | **Research domain/subdomain** |
| --- | --- | --- | --- | --- | --- |
| Wang, Zhao, Xu & Gu, 13 March 2, 2020<sup>1</sup> | China, Asia | To describe the urgency of blood glucose management during outbreak COVID-19 among diabetic patients | Unavailable information | 1. COVID-19 patients with diabetes had higher risk to develop septic shock and acute respiratory distress syndrome that make them easy to admit ICU (22.2%) or death (up to 7.3%). It is caused by stress condition and the increase of hyperglycemic hormones secretion, which results in abnormal variability of blood glucose, raised blood pressure, and complication. Tailored diabetes care and glycemic control are needed and adjusted regarding age, existing comorbidities, clinical manifestation and other risk factors. All hospitalized COVID-19 patients with diabetes are recommended to control blood glucose. When patients are discharged, a 4-week follow up of blood glucose homeostatic is monitored and they need to avoid infection. | 1. Diabetes management: glycemic control and monitoring, education |
| Brufsky, 15 April 2020<sup>1</sup> | US, America | To provide theoretical framework of hydroxychloroquine benefits to control viral load while COVID-19 infection | Unavailable information | 1. High fasting blood glucose was identified as independent predictor of SARS mortality. Present diabetes was correlated with ICU admission (22.5%–58%) and contributed for mortality (7.6%) among COVID-19 patients. 2. Glucocorticoid therapy was delivered for 44.9% non-ICU and 72.2% ICU patients with COVID-19 and it was associated with hyperglycemia and induced more severe clinical manifestation. Current review suggested the use of glucocorticoid in viral diseases was not recommended for COVID-19 pneumonia and it caused harm. 3. In the small-randomized trial, 62 COVID-19 patients with mild sign and symptoms of COVID-19 pneumonia (by CT scan), randomly received oral hydroxychloroquine 200 mg twice/day for 5 days. The 80.6% of patients improved their COVID-19 pneumonia findings (p = 0.047) and none of them developed severe COVID-19 pneumonia. 4. Among COVID-19 patients with diabetes, hydroxychloroquine works as oral hypoglycemic agent to reduce glycated hemoglobin and finally hyperglycemia. | 1. Diabetes management: medication |

(continued on next page)
| Author(s) & date of publication | Country/Region | Aim | Data collection | Key findings | Research domain/subdomain |
|--------------------------------|----------------|-----|----------------|-------------|--------------------------|
| Puig-Domingo, Marazuela, Giustina, 11 April 2020 | Spain, Europe | To provide endocrinologist statement in response with diabetes care during COVID-19 pandemic | | 1. People with diabetes are recommended to do physical distancing and stay at home as primary prevention strategies. All diabetic patients should adhere and be strict to avoid the infection during pandemic session. They should make a future plan about what to do while confinement and getting sick. Maintaining good glycemic control is important to reduce risk of infection and/or the severity of infectious diseases. Type 1-diabetes patients should contact endocrinologists while type 2 diabetes patients need to consult with internal medicine specialists or general practitioners. It, however, is not recommended to do regular appointment. It is recommended to consult through emails, phone calls or video calls. Patients need to supply blood glucose sticks as well as glucometer and make sure for adequate medication. 2. When diabetes patients are suspected due to having fever and cough or dyspnea/pneumonia or have a history of visit pandemic regions or contact with confirmed COVID-19 patient, they should seek physicians’ or nurses’ advice and follow the medical protocol. When patients are suggested to go to hospital, make sure they use facemask. Samples from nose or throat will be examined as diagnosis procedure. 3. In case of home confinement, patients and families should follow the rules for affected or suspected person to prevent further transmission and closed monitor of clinical manifestation. The suspected people should stay in single room with proper ventilation while others live in different room. If it is inapplicable, at least keep 1-m distance with the suspected person and do routine hand washing after any contact with or the surroundings. It is recommended to use paper towel after hand washing or clean towel but replace it when getting wet. The affected person should put medical mask to cover nose and mouth. All caregivers also need to wear full-covered medical mask when in the same room with the suspected person. | 1. Diabetes management: prevention |
| Banerjee, Chakraborty & Pal, 13 April 2020 | India, Asia | To review any aspects of diabetes self management education as patient center care | Authors used three databases (PubMed, Embase and Google Scholar) till March 29. The keywords were “COVID-19”, “diabetes self-care”, “diabetes self-management education”, “DSME”, “diabetes self-management in India”, “diabetes self-care in India” and “DSME in India” | 1. Policy of social distancing, isolation and lockdown affects diabetes care. Confinement may limit physical activities and limited stock of foods during lockdown could alter their dietary habits. Difficulty or limited procurement of medications and glucose strips may happen and they would not be able to do routine hospital visit. | 1. Diabetes management: education, dietary intake, physical activity, medication, glycemic control and monitoring. |
| Author(s) & date of publication | Country/Region | Aim Data collection | Key findings | Research domain/subdomain |
|-------------------------|----------------|-------------------|--------------|--------------------------|
| 2. Since regular visit is not recommended, it is suggested to utilize tele-consultation by smartphones to keep in touch with healthcare providers. |
| 3. Required calorie of daily intake for non-obese and obese patients is 22–25 kcal/kg and 20–25 kcal/kg of ideal body weights on sedentary lifestyle, respectively which distributed in three meals and a snack as their habits. Food composition should be maintained 50–60% (complex) carbohydrates, 25–45% fibers, no more than 30% fats, and 1 g/kg/day (general) or 0.8/kg/day (nephropathy and macro-albuminuria) for protein. Three teaspoons of oil/day (combined with 2 or more vegetable oils) and no more than 5 g of sodium in daily. Diabetes plate is recommended; half of plate is vegetable, one quarter of plate is proteins and the rest is complex carbohydrates. Sugar sweetened foods, smoking and drinking should be strictly avoided. Patients are recommended to do tele-consultation with nutritionist. |
| 4. Physical activities are suggested among diabetes patients in amount of 60 min/day, divided for aerobic, work-related and muscle-training activities. Moderate intensity of aerobic exercise for minimal 30-min/day e.g. brisk walking, treadmills, stationary cycling or jogging and gardening. If it is not achievable, patients should take two or three times in small portion 10–15 min. Climbing stairs and household chores for 15 min/day is suggested as work-related activities. A 15 min/day for muscle training exercise e.g. squats, push-ups, sit-ups, and forward flexes and resistance exercise (light weight), is recommended. Tailored exercise for intensity and type of activities should be addressed to individual patient and specific consideration should be noticed for patients with heart diseases and hypoglycemia history. |
| 5. Physicians and diabetes educators could monitor the adherence of medication through tele-consultation. The health care workers need to make sure patient’s compliance and could use online check of drugs to ensure they get adequate medication stocks. In addition, patients should be educated about contraindication of hydroxychloroquine, i.e. diabetic retinopathy and history of seizure, to avoid adverse effect of the treatment. |
| 6. Self-monitoring of blood glucose using capillary blood is suitable. Patients may find difficulty to get the strips amid COVID-19, then, taking online store of pharmacy and prior order before the strips are used, are recommended. Patients who (continued on next page) |
consume oral anti diabetes with acceptable outcomes, could test once to twice a week to monitor fasting and post prandial blood glucose. For those who administer insulin with recurrent hypoglycemia or poor glycemic control, should test minimum 4 times (fasting, pre-lunch, pre-dinner, and bedtime) a day. Any occasion when sign/symptom of hypoglycemia occurs, the prick test in capillary blood glucose should be conducted. All the monitoring should be recorded for at least 3 days and reported to health care workers while tele-consultation.

7. Elderly patients living with type 2 diabetes were experiencing high blood glucose that indicated poor glycemic control while pandemic COVID-19.

Singh, Gupta, Ghosh, Misra, 9 April 2, 020
India, Asia
To compile available evidences of prevalence, pathophysiology, prognosis and practical concerns among COVID-19 patients with diabetes

Two databases (PubMed and Google Scholar) were used with keywords 'COVID-19', 'SARS-CoV-2', 'diabetes', 'antidiabetic therapy' until April 2. Only full text articles were included.

1. There is not clear data of oral anti diabetic agents to treat COVID-19 infection. Although some oral agents of anti diabetic seem indicating positive outcome, there is no confirmed report about the role of anti diabetic agents in the context of COVID-19 treatment. Currently the application of ACE inhibitors and ARB is theoretically useful, however, to date there is no robust evidence to support. Although there was a lack of evidence about the effectiveness of ACE inhibitors and ARB for COVID-19 patients, European and American cardiology and Hypertension Association recommended it to treat COVID-19 patients.

2. Patients could perform self-checking and monitoring their blood glucose and the results should be communicated via phone to health care providers. Continues glucose monitoring potentially helps when the blood glucose records are accessible without visiting patients in remote areas. Patients may face difficulty in procuring strips, glucose-meters, needles and medicines.

3. The pandemic situation leads many regions conduct lockdown, which results home confinement. Patients with diabetes may have limited opportunity to do exercise e.g. regular walks, swimming or visiting gyms. Home exercise should be conducted e.g. treadmill, cycling, stationary jogging and resistance exercise.

4. Other impacts of lockdown make patients consume canned or packaged foods, which contain high calorie and/or fats. Limited access for fresh vegetables and fruits also can impact the patients during the pandemic COVID-19. Healthy and balanced diet should be always educated while consultation.

5. The elderly patients who are living alone may face more complicated problems as results of lockdowns.

6. Patients should notice an emergency situation that may happen such as

| Author(s) & date of publication | Country/ Region | Aim Data collection | Key findings | Research domain/subdomain |
|--------------------------------|-----------------|--------------------|--------------|--------------------------|
| Singh, Gupta, Ghosh, Misra, 9 April 2, 020 | India, Asia | To compile available evidences of prevalence, pathophysiology, prognosis and practical concerns among COVID-19 patients with diabetes | There is not clear data of oral anti diabetic agents to treat COVID-19 infection. Although some oral agents of anti diabetic seem indicating positive outcome, there is no confirmed report about the role of anti diabetic agents in the context of COVID-19 treatment. Currently the application of ACE inhibitors and ARB is theoretically useful, however, to date there is no robust evidence to support. Although there was a lack of evidence about the effectiveness of ACE inhibitors and ARB for COVID-19 patients, European and American cardiology and Hypertension Association recommended it to treat COVID-19 patients. | 1. Diabetes management: medication, glycemic control and monitoring, physical activity, dietary intake. |
| Author(s) & date of publication | Country/Region | Aim | Data collection | Key findings                                                                                                                                                                                                 | Research domain/subdomain |
|--------------------------------|----------------|-----|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Baretic, 13 April 2,020\(^{12}\) | Croatia, Europe | To illustrate care experience in type 1 diabetes patient undergoing Chloroquine therapy | Author reported the progress and treatment for COVID-19 patients with type 1 diabetes due to Chloroquine therapy. The entire situation should require hospital visit or admission. | 1. COVID-19 patient with type 1 diabetes who received Chloroquine therapy is potentially experiencing hypoglycemia as its side effect. Chloroquine agent has hypoglycemia and immunomodulatory effects; therefore, all type 1-diabetes patients who are undergoing Chloroquine therapy should be intensively monitored for their blood glucose.  
2. Chloroquine alone leads the increase of serum insulin level in diabetic animals through providing a signal to cellular receptors and post-receptor clearance. Lysosomotropic and immunomodulatory process are potentially associated with anti-inflammatory effect of Chloroquine. Thus, close monitoring is inevitable among type 1 diabetes patients treating with Chloroquine and it may require adjustment of insulin dose when needed. | 1. Diabetes management: medication. |
| Ghosh, Gupta, Misra, 4 April 2,020\(^{13}\) | India, Asia | To identify the feasibility of telemedicine practice for patients living with diabetes amid the COVID-19 pandemic | The keywords of ‘telemedicine’, ‘diabetes’, ‘COVID-19’ were implemented in two databases, PubMed and Google Scholar till March 2020. Authors also searched the available guideline  
1. Meta-analysis of RCT telemedicine through email, phone or video in China for 3–60 months, indicated significant reduction of HbA1c −0.37% (p < 0.001). Further review in Cochrane found similar pattern in which HbA1c reduction of −0.31% (p < 0.001). Current review of telemedicine among type 1 (n = 2052) and type 2 diabetes (n = 24,000) also indicated significantly reduction of HbA1c (−0.12% to −0.86% and −0.01% to −1.13%, respectively).  
2. The recommended telemedicine is video mode approach for first consult. Keep maintain patient’s privacy, confidentiality and consent from patients or surrogates or caregivers are crucial points. Medical records should be completed with radiology and laboratory findings and prescription. In case of impossible application of telemedicine, consultation could be done in face-to-face but it should consider appropriate place and time to prevent transmission. Telemedicine is not appropriate to prescribe any psychotropic or narcotic agents. History of previous complaints, allergy, and medical records (including hypoglycemia) should be obtained. On the other hand, clinical examination is not able to perform. Video or photograph could help when finding any lesion on foot, abscess or other visible wounds. Any noticeable neurological deficit could be identified through consultation or ask patients to perform several simple and independent neurological assessment. When, it is no doable, patients should visit clinic for comprehensive assessment.  
2. Specific consideration: pregnancy, children and adolescent, emergency or critical care | 1. Diabetes management: education, dietary intake, physical activity, and medication. |
Adjustment of sulfonylurea and insulin dose may be necessary to prevent hypoglycemia. All diabetes patients should be provided information on adverse effects of anti-diabetic agents and encourage them to report any adverse effect [13]. Additionally, it was reported that 44.9% non-ICU and 72.2% ICU patients with COVID-19 received glucocorticoid therapy as daily treatment. Glucocorticoid was associated with hyperglycemia and induced more severe clinical manifestation. Recent review found that the use of glucocorticoid was not recommended to treat COVID-19 pneumonia and could cause harm [11].

Previous reported COVID-19 patients obtained a hydroxychloroquine therapy. In a small-randomized trial, COVID-19 patients with mild sign/symptom of pneumonia (by CT scan), received oral hydroxychloroquine 200 mg twice a day for five days. About 80.6% patients indicated improvement of COVID-19 pneumonia and none developed severe COVID-19 pneumonia. Among COVID-19 patients with diabetes, hydroxychloroquine works as hypoglycemia agent by decreasing HbA1c and hyperglycemia [11]. COVID-19 patients with type 1 diabetes who receive Chloroquine therapy is potentially experiencing hypoglycemia as its side effect. Chloroquine agent has hypoglycemia and immunomodulatory effects, and therefore all patients should be closely monitored. In diabetic animals, Chloroquine causes an increase in the level of insulin serum by providing a signal to cellular receptors and post-receptor clearance [12]. All diabetic patients who receive hydroxychloroquine should obtain education on the contraindication such as diabetic neuropathy and history of seizure [7].
Mended that patients with diabetes should arrange an individual preventive method. They should avoid contacts or exposure with COVID-19 infection. In general, diabetes patients should adhere and psychotropic/narcotic prescription [13].

A video mode of telemedicine is also recommended for the first consultation. Patient’s privacy, confidentiality, and consent (from surrogates, caregivers or patients) should be maintained. Radiology, laboratory findings and prescription should be integrated in medical records. Previous history of complaint, allergy, and hypoglycemia are of main concern. Identification of any noticeable neurological deficit is applicable by requesting patients to perform simple neurological test. Video or photograph could help when suspecting any lesion on foot, abscess or visible wound. All patients should recognize sign/symptom of hypoglycemia and know how to treat it. Health care providers should always remind patients to do hand washing, cough technique and social distancing as general precaution during tele-consultation. When telemedicine or tele-consultation is not compatible, face-to-face clinic visit is acceptable by considering time and place for preventing transmission of Cavid19. Telemedicine is also not doable for clinical examination and psychotropic/narcotic prescription [13].

4.1.6. Prevention of COVID-19 infection

As previously reported, patients with diabetes are at higher risk for COVID-19 infection. In general, diabetes patients should adhere to social distancing and home confinement policy as primary preventive method. They should avoid contacts or exposure with confirmed COVID-19 patients as much as they can. It is recommended that patients with diabetes should arrange an individual plan of diabetes management while staying at home or getting sick. They can make a to do list for dietary intakes, physical activities, and stress management during confinement. All diabetes patients are strongly recommended to keep maintaining their glycemic control as part of risk reduction of infection and/or prevent severe consequence of infection for confirmed COVID-19 patients with diabetes [5,8].

All diabetes patients should visit hospital to consult with physicians or nurses when they are suspected of COVID-19 infection. Fever and cough, dyspnea or pneumonia, visiting a pandemic area and recent contact with confirmed COVID-19 patients are factors for diabetes patients to be suspected as COVID-19 infection. When patients decide to go to hospital or clinic, patients with diabetes should use face masks. They will undergo diagnosis procedure by taking samples from noses or throat [5].

In case of home confinement, patients and families should adhere to the rules for affected or suspected people because it could help to prevent further transmission to other patients and/or families. The affected people should live in a single room with proper ventilation, meanwhile other family members stay in different room. If this is not applicable, make sure to always keep a minimum 1-m distance from the affected person, routine hand washing after any contact with the affected patient or the environment and use disposable paper towel or clean towel (and replace it when it is getting wet) after hand wash. The affected person should use medical mask to cover nose and mouth. All caregivers also need to wear full-covered medical mask when being in the same room with the affected person [5].

4.2. Specific consideration

Diabetes management is inevitably altered during the COVID-19 pandemic. Therefore, specific condition is required for specific circumstances. The following section will discuss diabetes management in a certain population or situation based on the current available evidences.

4.2.1. Diabetes in children and adolescents

In child or adolescent with newly diagnosed type 1 diabetes, it is recommended to take face-to-face mode of consultation. Type 1 diabetes patients and families should visit diabetes clinic to initiate insulin administration. Health care providers should make sure that patients and families receive diabetes education with highlighted topic on insulin administration, hypoglycemia and ketoacidosis sign/symptom and management. For the follow up of type 1 diabetes patients, ketoacidosis test should be advised when experiencing hyperglycemia [13].

4.2.2. Diabetes in pregnancy

All patients with gestational diabetes should undergo face-to-face consultation for insulin initiation during their first visit. Patients should obtain tailored education related their diabetes and current condition for lifestyle management. Minor adjustment of insulin dose may be necessitated for follow up gestational diabetes patients using telemedicine/tele-consultation [13].

4.2.3. Diabetes in elderly

Elderly patients with diabetes are more likely to have deteriorated glycemic control as result of raised blood glucose amid COVID-19 pandemic [7]. Hyperglycemia or hypoglycemia could occur due to limited access of care during lockdown and quarantine, which stimulate unstable blood glucose. It can lead to further serious complication for elderly patients with diabetes for example ketoacidosis, infection, coma hyperosmolar, and cardiac event. The drawback is more distinct among elder diabetic patients who live alone [2]. It is recommended to encourage them and always keep in touch with health care providers and quickly seek for help when needed.

4.2.4. Emergency or critical situation

All diabetic patients who are experiencing drowsiness, vomiting, chest pain, short of breath, limb weakness, and altered sensory should be noticed as emergency situation [9]. In addition, diabetic patients with any foot lesion, gangrene, severe hypoglycemia, gastroenteritis, and any other infection related to COVID-19 should be addressed for special condition. All of these situations require hospital/clinic visit or admission [13]. Health care providers should make sure diabetic patients understand about those signs/symptoms and take initial action to hospital/clinical appointment.

For confirmed COVID-19 patients with diabetes who receive critical care, intensive blood glucose monitoring should become priority of care. Adverse effect of drug reaction should be early identified [8]. Diabetes has noticed an independent factor of ICU admission and raised risk of mortality rate [3,7,11]. It was reported that COVID-19 patients with diabetes comorbidity had twice the risk to be admitted ICU and receive critical care [3]. Other study described that COVID-19 patients with diabetes contributed to
22.2%–58% of ICU admission due to septic shock and acute respiratory distress syndrome as result of blood glucose variability and elevated blood pressure [8,11]. The mortality risk of COVID-19 patients with diabetes is three times higher than non-diabetic patients [3]. Current reports noted the mortality rate of COVID-19 patients with diabetes was 7.3%–7.6% [8,11]. Thus, all health care providers should more concern when caring COVID-19 patients with diabetes during hospitalization.

4.3. Limitation

This is a scoping review to provide broader scope of diabetes management and action for particular consideration. Thus, there was no included level of evidence and quality evaluation. In addition, there was unclear methodological approach among included articles (author(s) did not definitely express the method section). Three included articles did not provide clear information about study design and data collection process. Five out of seven included articles did not specify the sample size and one article used one-sample size (case report). The limitation on the included studies causes a limitation for this scoping review.

5. Conclusion

This review produced a summary of diabetes management and specific considerations amid the COVID-19 pandemic for diabetes patients. Patients and family members could use this review to deal with diabetes management, concern on particular situations of diabetes, and seek for help when needed. Health care providers and policy makers could take concern on review results to facilitate people living with diabetes passing through the COVID-19 pandemic.

Funding

There is no funding available.

Availability of data and materials

Data are available by contacting the corresponding author with reasonable reasons.

Authors’ contribution statement

ALW, NSH, AF designed study and guided methodology. ALW and NSH were responsible for searching, selection, data extraction and wrote the first draft. AF and RBP reviewed and discussed the manuscript. All authors approve and responsible for publication.

Ethic approval and participant consent

Not applicable.

Consent for publication

Not applicable.

Declaration of competing interest

The authors declare that there is no conflict of interest.

Acknowledgments

We would appreciate librarians in Universitas Gadjah Mada, Indonesia that facilitate our review.

References

[1] Hussain A, Bhownik B, do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract 2020 Apr 9;162:108142. https://doi.org/10.1016/j.diabres.2020.108142.
[2] Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr Clin Res Rev 2020 Apr 9;14(4):303–10. https://doi.org/10.1016/j.dsx.2020.04.004.
[3] Roncon L, Zuin M, Rigarelli c, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol 2020;127:104354. https://doi.org/10.1016/j.jcv.2020.104354.
[4] Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metabolism 2020 Mar 24;107:154217. https://doi.org/10.1016/j.metabol.2020.154217.
[5] Puig-Domingo M, Marazuela M, Guistina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 2020 Apr 11;68:2–5. https://doi.org/10.1007/s12020-020-02294-5.
[6] Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020 Mar 11;109:531–8. https://doi.org/10.1007/s00392-020-01626-9.
[7] Banerjee M, Chakraborty S, Pal R. Diabetes self-management amid COVID-19 pandemic. Diabetes Metab Syndr Clin Res Rev 2020 Apr 13;14(4):351–4. https://doi.org/10.1016/j.dsx.2020.04.013.
[8] Wang A, Zhao W, Xu Z, Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract 2020 Mar 13:162. https://doi.org/10.1016/j.diabres.2020.108118.
[9] Arksney H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2007 Feb 23;8:19–32. https://doi.org/10.1080/ 13645572000119616.
[10] Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic review. Ann Intern Med 2009;151(4):264–9. https://doi.org/10.7326/0003-4819-151-4-200908180-00115.
[11] Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol 2020 Apr 15;92:770–5. https://doi.org/10.1002/jmv.25887.
[12] Baretic M. Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: what should we have in mind during the COVID-19 pandemic? Diabetes Metab Syndr Clin Res Rev 2020 Apr 13;14(4):355–6. https://doi.org/10.1016/j.dsx.2020.04.014.
[13] Ghosh A, Gupta R, Misra A. Telemedicine for diabetes care in India during COVID-19 pandemic and national lockdown period: guidelines for physicians. Diabetes Metab Syndr Clin Res Rev 2020 Apr 4;14(4):273–6. https://doi.org/10.1016/j.dsx.2020.04.001.
[14] American Diabetes Association. Summary of revisions: standards of medical care in diabetes-2019. Diabetes Care 2019 Jan;42(Supplement1):S54–6. https://doi.org/10.2337/dc19-S004.
[15] American Diabetes Association. Lifestyle management: standards of medical care in diabetes-2019. Diabetes Care 2019 Jan;42(Supplement1):S46–60. https://doi.org/10.2337/dc19-S004.
[16] American Diabetes Association. Diabetes care in the hospital: standards of medical care in diabetes-2019. Diabetes Care 2019 Jan;42(Supplement1):S173–81. https://doi.org/10.2337/dc19-S015.
[17] Putranti DP, Pulo EO, Anita C, Wicaksana AL. Effect of yoga on pulmonary function among asthmatic patients: a protocol synthesis. Enferm Clin 2020 Apr 21;30(Supplement3):136–42. https://doi.org/10.1016/j.jencli.2010.12.044.
[18] Zhai YK, Zhu WJ, Cai YL, Sun DX, Zhao J. Clinical- and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis. Medicine 2014 Dec;93(28):e312. https://doi.org/10.1097/MD.0000000000000312.
[19] Timpel P, Oswald S, Schwarz PEH, Harst L. Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: an umbrella review of systematic reviews and meta-analyses. J Med Internet Res 2020 Mar 18;22(3):e16791. https://doi.org/10.2196/16791.